Galera Therapeutics (GRTX) Stock Chart & Stock Price History $0.02 +0.00 (+2.27%) As of 08/15/2025 11:54 AM Eastern Add Compare Share Share Chart Stock AnalysisChartCompetitorsInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock Galera Therapeutics Stock Price Performance The Galera Therapeutics (GRTX) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 70.78%, with a year-to-date return of -50.87%. In the past month, the stock has decreased 24.75%, reflecting recent market activity. As of the latest close, Galera Therapeutics traded at $0.02 with a market cap of $1.70 million and volume of 7,670 shares. Five years ago, the stock traded at $7.81, representing a 99.71% decrease over that period. At the time, it had a market cap of $206.83 million and a volume of 5,489 shares. Receive GRTX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Galera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-1.32%1 Month Performance-24.75%3 Month Performance-5.86%Year-To-Date Performance-50.87%1 Year Performance-70.78%5 Year Performance-99.71% GRTX Stock Chart for Saturday, August, 16, 2025 GRTX Chart by TradingView Galera Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/15/2025$0.02$0.02+2.27%$0.02$0.027,670 shs$1.70 million08/14/2025$0.02$0.02-2.65%$0.03$0.02159,553 shs$1.66 million08/13/2025$0.02$0.02-3.00%$0.03$0.02206,876 shs$1.71 million08/12/2025$0.02$0.02+2.19%$0.02$0.02106,340 shs$1.76 million08/11/2025$0.02$0.02-0.87%$0.02$0.0252,903 shs$1.72 million08/08/2025$0.02$0.02-3.36%$0.03$0.028,219 shs$1.74 million08/07/2025$0.02$0.02+3.48%$0.02$0.024,146 shs$1.80 million08/06/2025$0.02$0.02$0.02$0.0218,093 shs$1.74 million08/05/2025$0.02$0.02+2.22%$0.02$0.0235,716 shs$1.74 million08/04/2025$0.02$0.02-2.17%$0.02$0.02694 shs$1.70 million Get the Latest News and Ratings for GRTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Galera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 08/01/2025$0.02$0.02-4.17%$0.03$0.028,409 shs$1.74 million07/31/2025$0.03$0.02-7.69%$0.03$0.029,692 shs$1.81 million07/30/2025$0.02$0.03+5.69%$0.03$0.02158,664 shs$1.96 million07/29/2025$0.03$0.02-5.02%$0.03$0.02263,019 shs$1.86 million07/28/2025$0.03$0.03+3.60%$0.03$0.031,479 shs$1.95 million07/25/2025$0.02$0.03+5.93%$0.03$0.0258,672 shs$1.89 million07/24/2025$0.02$0.02-3.67%$0.03$0.02171,546 shs$1.78 million07/23/2025$0.02$0.02-0.81%$0.03$0.0214,951 shs$1.85 million07/22/2025$0.03$0.02-3.14%$0.03$0.02375,479 shs$1.86 million07/21/2025$0.03$0.03+1.19%$0.03$0.0381,103 shs$1.92 million07/18/2025$0.03$0.03-5.26%$0.03$0.0338,067 shs$1.90 million07/17/2025$0.03$0.03-11.04%$0.03$0.0340,433 shs$2.01 million07/16/2025$0.03$0.03-0.33%$0.03$0.0327,082 shs$2.26 million07/15/2025$0.03$0.03+15.38%$0.03$0.0326,100 shs$2.26 million Related Companies ACXP Stock Chart INAB Stock Chart ARTL Stock Chart MYNZ Stock Chart CDIO Stock Chart SBFM Stock Chart HCWB Stock Chart AEZS Stock Chart APLM Stock Chart NKGN Stock Chart Receive GRTX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Galera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:GRTX) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredJPMorgan: Gold to $4,250—Here’s the Real PlayGold Surges And Some Investors Are Getting Paid, But Most Are Not. Which One Do You Want to Be? Gold prices ar...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access